Anemia in Lymphoproliferative Disorders.
نویسنده
چکیده
The etiologies of anemia in patients with lymphoproliferative disorder (LPD) are diverse. Causes such as acute blood loss or deficiencies in iron or vitamins (folate/B12) are considered in the initial evaluation. In many instances, the anemia can be attributed to marrow infiltration by the LPD. Treatment with chemotherapy can suppress erythropoiesis. Other causes that occur more often with LPD are autoimmune phenomena such as autoimmune hemolytic anemia (AIHA) or pure red cell aplasia (PRCA). Finally, after excluding these conditions, anemia of chronic disease (ACD) is considered as the basis for the anemia.
منابع مشابه
Aplastic anemia evolving to myelodysplastic syndrome and later to a lymphoproliferative malignancy in a treated case of carcinoma breast: A case report emphasizing the importance of PET-CT in cutaneous T cell lymphoma
Although aplastic anemia (AA) and myelodysplastic syndrome (MDS) are separate entities with different management, distinction between the two can be difficult on morphological basis due to hypocellularity of bone marrow. MDS is one of the serious complications of AA. Karyotyping is definitive in the diagnosis of MDS. Better and robust investigations like 18F-Fluoro-deoxy-Glucose Posi...
متن کاملSubcutaneous Erythropoietin for Treatment of Refractory Anemia in Hematologic Disorders. Results of a Phase
We have used recombinant human erythropoietin (rHuEPO) in a phase 1/11 clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 t o 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level 2 10 g/dL without blood transfusion. Of 25 patients treated, 17 were evaluable, m...
متن کاملSubcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders.
We have used recombinant human erythropoietin (rHuEPO) in a phase 1/11 clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 t o 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level 2 10 g/dL without blood transfusion. Of 25 patients treated, 17 were evaluable, m...
متن کاملAutoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment.
Autoimmunity and immune dysregulation may lead to cytopenia and represent key features of many primary immunodeficiencies (PIDs). Especially when cytopenia is the initial symptom of a PID, the order and depth of diagnostic steps have to be performed in accordance with both an immunologic and a hematologic approach and will help exclude disorders such as systemic lupus erythematosus, common vari...
متن کاملSubcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
We have used recombinant human erythropoietin (rHuEPO) in a phase I/II clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 to 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level greater than or equal to 10 g/dL without blood transfusion. Of 25 patients treated...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cancer control : journal of the Moffitt Cancer Center
دوره 5 2 Suppl 1 شماره
صفحات -
تاریخ انتشار 1998